OnCo

Nasopharyngeal carcinoma: lines of therapy

Cancer page →

4 standard-of-care settings across 3 lines and 1 biomarker subgroup. Rows come from the cancer page's standard of care; the grid places each on its line and subgroup.

LineAll comers
Early / localised2
Advanced, first line1
Second line1

Early / localised

SubgroupSettingApproachProducts and trialsEvidence
All comersStage IIMRT alone (70 Gy) to nasopharynx and elective neck.91
All comersStage II-IVAInduction gemcitabine-cisplatin ×3 then concurrent cisplatin-IMRT (for stage III-IVA); concurrent chemoradiation alone for stage II; adjuvant capecitabine for high-risk (detectable post-RT EBV DNA, N2-3).91

Advanced, first line

SubgroupSettingApproachProducts and trialsEvidence
All comersRecurrent/metastatic, first lineGemcitabine-cisplatin + PD-1 inhibitor (toripalimab, camrelizumab, tislelizumab or penpulimab), then PD-1 maintenance.89

Second line

SubgroupSettingApproachProducts and trialsEvidence
All comersLocal recurrenceEndoscopic or open nasopharyngectomy for resectable rT1-3 (better survival than re-irradiation, Liu Lancet Oncol 2021); hyperfractionated re-IMRT otherwise.91

Regimens in the library

Lines and subgroups are parsed from the setting text of each standard-of-care row and can misclassify an unusual phrasing; the row’s own setting is always shown. Guideline chips reflect the NCCN category and ESMO-MCBS grade recorded on the cancer page, checked on its stated date. Not medical advice.